Articles & Publications
Dr. Chism’s work spans clinical oncology, clinical trials, cancer care delivery, immunotherapy, health services research, workforce issues, and translational science.
This page brings together articles created for the website with his supplied record of publications, abstracts, book chapters, reviews, case reports, and invited commentaries.
Publications
ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States.
Erin P. Balogh, Laura A Levit, Joseph M. Unger, et.al. JCO Oncology Practice. 2025 Oct 21 pages 1746-1758.
Where have we been and where are we Going? The state of hematology and medical oncology workforce in America.
M. Kelsey Kirkwood, Erin P. Balogh, Melissa K. Accordino et. Al. JCO Oncology Practice 21, 1775-1785(2025).
First-Line Camizestrant for Emerging ESR1-mutated advanced breast cancer.
Francois-Clement Bidard, Erica L Mayer, Yeon Hee Park, et. Al., NEJM. 2025 Aug 7;393(6):569-580.
Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in patients with Metastatic urothelial carcinoma.
Petrylak Daniel P, Eigl Bernhard J, George Saby, et.al, Clin Cancer Research. 2024 Jan 5:30(1):63-73. Doi: 10.1158/1078-0432.
Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
Wang DY, Salem JE, Cohen JV, et. al, .JAMA Oncol. 2018 Dec 1;4(12):1721-1728. PMID: 30242316
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Kuderer NM, Choueiri TK, Shah DP, et.al; COVID-19 and Cancer Consortium.Lancet. 2020 Jun 20;395(10241):1907-1918. PMID: 32473681
Publications
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
Gilligan T, Lin DW, Aggarwal R, et. al, J Natl Compr Canc Netw. 2019 Dec;17(12):1529-1554. PMID: 31805523
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.
Grivas P, Khaki AR, Wise-Draper TM, et. al, Ann Oncol. 2021 Jun;32(6):787-800. PMID: 33746047
Interplay of Immunosuppression and Immunotherapy Among Patients with Cancer and COVID-19.
Bakouny Z, Labaki C, Grover P, et. al, COVID-19 and Cancer Consortium.JAMA Oncol. 2023 Jan 1;9(1):128-134.PMID: 36326731
Racial Disparities in COVID-19 Outcomes Among Black and White Patients with Cancer.
Fu J, Reid SA, French B, et. al, COVID-19 and Cancer Consortium (CCC19). JAMA Netw Open. 2022 Mar 1;5(3): e224304. PMID: 35344045
Assessment of Regional Variability in COVID-19 Outcomes Among Patients with Cancer in the United States.
Hawley JE, Sun T, Chism DD et. al, COVID-19 and Cancer Consortium (CCC19). JAMA Netw Open. 2022 Jan 4;5(1): e2142046.
Association of Convalescent Plasma Therapy with Survival in Patients with Hematologic Cancers and COVID-19.
Thompson MA, Henderson JP, et. al,; COVID-19 and Cancer Consortium.JAMA Oncol. 2021 Jun 17;7(8):1167-75. PMID: 34137799
Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
Chism DD. J Natl Compr Canc Netw. 2017 Oct;15(10):1277-1284. PMID: 28982752
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer.
Chism DD, De Silva D, Whang YE. Expert Rev Anticancer Ther. 2014 Nov;14(11):1369-78. Epub 2014 Jun 13. PMID: 24927631
Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement from the American Heart Association.
Campia U, Moslehi JJ, Amiri-Kordestani L, Barac A, Beckman JA, Chism DD, Cohen P, Groarke JD, Herrmann J, Reilly CM, Weintraub NL. Circulation. 2019 Mar 26;139(13): e579-e602. doi: PMID: 30786722
Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.
Chism DD, Woods ME, Milowsky MI. Oncologist. 2013;18(8):933-40. doi: 10.1634/theoncologist.2013-0023. Epub 2013 Jul 24. PMID: 23883869
Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer.
Chism DD, Rathmell WK. Nat Rev Nephrol. 2016 Jun;12(6):317-8. doi: 10.1038/nrneph.2016.58. Epub 2016 Apr 25. PMID: 27108841
Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes.
Chism DD, Rathmell WK. Clin Cancer Res. 2014 Apr 1;20(7):1721-3. doi: 10.1158/1078-0432.CCR-14-0056. Epub 2014 Mar 14. PMID: 24634386 Free PMC article.
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology.
Damrauer JS, Hoadley KA, et. al. Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):3110-5. doi: 10.1073/pnas.1318376111. Epub 2014 Feb 11. PMID: 24520177 Free PMC article.
A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.
COVID-19 and Cancer Consortium. COVID-19 and Cancer Consortium. Cancer Cell. 2020 Dec 14;38(6):761-766. doi: 10.1016/j.ccell.2020.10.022. Epub 2020 Oct
Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy.
Rose TL, Chism DD, Alva AS, et. al. Br J Cancer. 2018 Oct;119(7):801-807. Epub 2018 Oct 8. PMID: 30293995
Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A, Carlo MI, Barthélémy P, et. al, J Immunother Cancer. 2018 Dec 27;6(1):159. PMID: 30591082
Metachronous Bilateral Testicular Leydig-Like Tumors Leading to the Diagnosis of Congenital Adrenal Hyperplasia (Adrenogenital Syndrome).
Vukina J, Chism DD, Sharpless JL, et. al. Case Rep Pathol. 2015; 2015:459318. doi: 10.1155/2015/459318. Epub 2015 Aug 16. PMID: 26351608
Ozone-induced airway hyperresponsiveness is reduced in immature mice.
Shore SA, Johnston RA, Schwartzman IN, et. al. J Appl Physiol (1985). 2002 Mar;92(3):1019-28. PMID: 11842035.
A Case Report of Severe Type B Lactic Acidosis Following First Dose of Nivolumab in a VHL-Mutated Metastatic Renal Cell Carcinoma.
Nakajima E, Leger P, Mayer IA, et. al. Kidney Cancer. 2017 Jul 26;1(1):83-88. PMID: 30334008
Effect of Concomitant pH-Elevating Medications with Pazopanib on Progression-Free Survival and Overall Survival in Patients with Metastatic Renal Cell Carcinoma.
McAlister RK, Aston J, Pollack M, et. al. Oncologist. 2018 Jun;23(6):686-692. 2017-0578. Epub 2018 Feb 27. PMID: 29487220
Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma.
Margulis V, Puligandla M, Trabulsi EJ, et. al, Collaborators. J Urol. 2020 Apr;203(4):690-698. Epub 2019 Nov 8. PMID: 31702432
IL-13 and IL-4 cause eotaxin release in human airway smooth muscle cells: a role for ERK. Moore PE, Church TL, Chism DD, et. al. Am J Physiol Lung Cell Mol Physiol. 2002 Apr;282(4):L847-53 PMID: 11880312
Development of a polyclonal antiserum for the detection of the isoforms of the receptors for human growth hormone-releasing hormone on tumors.
Toller GL, Horvath JE, Schally AV, et. al.Proc Natl Acad Sci U S A. 2004 Oct 19;101(42):15160-5. Epub 2004 Oct 6. PMID: 15469915
Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Ricciardi MR, McQueen T, Chism D, et. al. Leukemia. 2005 Sep;19(9):1543-9. PMID: 16001087
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial.
Choueiri TK, Larkin J, Oya M, Thistlethwaite F, Martignoni M, Nathan P, Powles T, McDermott D, Robbins PB, Chism DD, Cho D, Atkins MB, Gordon MS, Gupta S, Uemura H, Tomita Y, Compagnoni A, Fowst C, di Pietro A, Rini BI. Lancet Oncol. 2018 Apr;19(4):451-460.PMID: 29530667
Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
Engel JB, Keller G, Schally AV, Nagy A, Chism DD, Halmos G. Fertil Steril. 2005 Apr;83 Suppl 1:1125-33. PMID: 15831285
Targeting Survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemia cells. Carter BZ, Wang RY, Schober WD, Milella M, Chism D, Andreeff M. Cell Cycle. 2003 Sep-Oct;2(5):488-93. PMID: 12963850. Konopleva M, Elstner E, McQueen TJ, Tsao T, Sudarikov A, Hu W, Schober WD, Wang RY, Chism D, Kornblau SM, Younes A, Collins SJ, Koeffler HP, Andreeff M. Mol Cancer Ther. 2004 Oct;3(10):1249-62. PMID: 15486192
Abstracts
Matt D. Galsky, Sumanta K. Pal, Amir Mortazavi, et. al.
Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.
Clin Oncol 37, 2019 (suppl; abstr 4504).
Gopalakrishnan, R, Johnson, DB, York, S, et. al.
Impact of the influenza vaccination on cancer patients undergoing therapy with immune checkpoint inhibitors (ICI).
J Clin Oncol, 2018 (suppl: abstr 3053).
Choueiri, TK, Larkin, JMG, Oya, M, et. al.
First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial. J Clin Oncol 315, 2017 (suppl; abstr 4504).
Johnson, DB, Moslehi, JJ, Beckermann, KE, et. al.
Long-Term and Cardiometabolic Effects of Anti-PD-1/PD-L1 Agents.
J Natl Compr Cancer Network 2017; 15:657-670.
Boilève, A, Voss, MH, Barthélémy, P, et. al. Immune checkpoint inhibitors following targeted therapies in MITF family translocation renal cell carcinomas.
ESMO Abstract 1165P, 2017.
Kardos, J, Melquist, J, Chism, DD, et.al.
Evaluation of basal and luminal subtypes of urothelial carcinoma in African American and non-African American patients.
J Clin Oncol 33, 2015 (suppl 7; abstr 305).
Chism DD, Damrauer, JS, Miller A, et. al.
BASE47 gene set predictor as an identifier of “basal-like” subtype of urothelial carcinoma of the bladder in African Americans.
J Clin Oncol 32, 2014 (suppl 4; abstr 300).
Chism DD, Damrauer, JS, Gallagher SA, et. al.
African Americans and Bladder cancer, Defining Intrinsic biology, and Outcome.
J Clin Oncol 31, 2013 (suppl; abstr e15595).
Characterizing fatal immune related adverse events (irAEs) from immune checkpoint inhibitors.
Wang, DY, Salem, J-E, Cohen, JV, et.al.
Book Chapters, Reviews, Case reports, and Invited Commentaries
Chism DD.
Urothelial Carcinoma of the Bladder and the Rise of Immunotherapy.
J Natl Compr Cancer Netw. 2017 Oct;15(10):1277-1284. PMID:28982752.
Nakajima E, Leger P, Mayer IA, Neuss M, Chism DD and Rathmell WK.
A case report of severe type B lactic acidosis following first dose of nivolumab in a VHL-mutated metastatic renal cell carcinoma.
Kidney Cancer, volume 1, no. 1, pp. 83-88, 2017.
Chism, DD and Rathmell WK.
Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer.
Nat Rev Nephrol. 2016 Apr 25. PMCID: PMC4871728.
Chism, D, Apolo, A, Milowsky, M.
Chemotherapy for Metastatic Bladder Cancer. In: Advances in Bladder Cancer Management.
Xylinas E, Shariat SF (Eds.). Future Science, London, UK (2015).
Chism, DD and Rathmell, WK.
Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes.
Clin Cancer Res; 2014;20(7); 1721-3. PMCID: PMC4077661
Chism, D, Rathmell, K.
Prognostic and Predictive Biomarkers in Renal Cell Carcinoma. In: Renal Cell Carcinoma.
Nizar Tannir. (Editor). Oxford American Oncology Library, New York, NY (2014).
